Intra-Cellular Therapies logo
Intra-Cellular Therapies ITCI

Annual report 2024
added 02-21-2025

report update icon

Intra-Cellular Therapies Gross Profit 2011-2026 | ITCI

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Intra-Cellular Therapies

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - - - 91.4 K 577 K - 3.12 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.12 M 91.4 K 1.26 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
-1.72 M - 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
9.02 K - 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
19.4 M - - $ 2.18 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
12 M - -14.27 % $ 1.7 M singaporeSingapore
AstraZeneca PLC AstraZeneca PLC
AZN
48.1 B - - $ 96.9 B britainBritain
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
63.5 M $ 2.02 - $ 189 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
339 M $ 1.42 - $ 166 M usaUSA
Abcam plc Abcam plc
ABCM
270 M - - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Affimed N.V. Affimed N.V.
AFMD
19.8 M - -34.95 % $ 21.5 M germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Celyad Oncology SA Celyad Oncology SA
CYAD
5 K - - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
53.8 M - -7.31 % $ 87 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
5.48 M $ 29.6 - $ 1.97 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
42.7 M $ 30.53 1.94 % $ 821 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
1.94 M - -4.36 % $ 27 M usaUSA
Exelixis Exelixis
EXEL
935 M $ 52.99 - $ 14.4 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
63.8 M $ 14.57 - $ 209 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
2.65 M - 5.93 % $ 314 M canadaCanada
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
2.03 M $ 2.91 - $ 4.79 M israelIsrael
Aptinyx Aptinyx
APTX
1.56 K - -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA